

Extension of Share Purchase Plan

Key Highlights:

- Extension of Prescient Therapeutics Share Purchase Plan targeting to raise up to \$7 million, with revised closing date to be Tuesday, 22 July 2025 at 5pm (AEST).
- Funds raised will be used to advance PTX-100 through Phase 2 clinical development toward potential regulatory approval.
- Shareholders can request an electronic copy of their personalised [Share Purchase Plan form here](#).

MELBOURNE Australia, 15 July 2025 – Prescient Therapeutics (ASX: PTX), an ASX-listed biotechnology company developing targeted and personalised medicines for cancer, advises that the closing date for the Share Purchase Plan (SPP) announced to the market on 1 July 2025 will be extended from Tuesday, 15 July 2025 to Tuesday, 22 July 2025 at 5.00pm (AEST).

The extension of the SPP closing date is to allow eligible shareholders additional time to complete applications, after having received feedback from several shareholders requesting additional time to participate due to the delay in accessing the documentation.

Under the SPP new fully paid ordinary shares will be issued at \$0.040 per share, equivalent to a 16.7% discount to the volume weighted average price (**VWAP**) over the 15 trading days before the date the SPP was announced.

The Company will offer Eligible Shareholders who were registered shareholders as at 7:00pm (AEST) on Monday, 30th June 2025 (**Record Date**) the opportunity to apply for up to A\$30,000 of new fully paid ordinary shares (**New Shares**) in the Company under the SPP.

For personal use only

An updated timetable with the new closing date for the SPP is as follows:

Event	Indicative Date
Record Date	7.00pm (AEST) on Monday, 30th June 2025
Announcement of SPP Offer and lodgment of Appendix 3B	Tuesday, 1st July 2025
SPP Opens & Dispatch of SPP Offer Booklet	Wednesday, 2nd July 2025
Revised SPP Closes	5.00pm (AEST) on Tuesday, 22nd July 2025
Revised SPP results announced to the ASX	Monday, 28th July 2025
Revised Issue of Shares under SPP	Wednesday, 30th July 2025
Revised Trading of all SPP Shares (subject to ASX listing rules)	Thursday, 31st July 2025
Revised Dispatch of holding statements to Eligible Shareholders participating in the SPP	Thursday, 7th August 2025

In accordance with the instructions in the SPP booklet and on the personalised Application Form, Eligible Shareholders may apply using BPAY or by completing the Application Form and returning it to Prescient’s share registry together with payment via Electronic Funds Transfer order by 5.00pm (AEST) on Tuesday, 22 July 2025.

Participate in the Share Purchase Plan

Shareholders can request an electronic copy of their personalised Share Purchase Plan application form be emailed to them from the below link:

<https://prescienttherapeutics.investorportal.com.au/share-purchase-plan-opportunity-request/>

Reach Corporate are the advisers managing the Share Purchase Plan and can be contacted on 1300 805 795 or via advisers@reachmarkets.com.au

For personal use only

Join a shareholder briefing

Join the CEO of PTX James McDonnell for a live and interactive shareholder briefing on Thursday, 17th July 12pm (AEST) where he will discuss the Share Purchase Plan, use of funds and how to participate.

Register here: <https://prescienttherapeutics.investorportal.com.au/shareholder-briefing-spp/>

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

For more information please contact:

Company enquiries

James McDonnell
CEO
Prescient Therapeutics
james.mcdonnell@ptxtherapeutics.com
www.ptxtherapeutics.com

Media enquiries

Reach Markets
1300 805 795
ir@reachmarkets.com.au

Corporate enquiries

Christian Riedel, CFA
0480187650
christian.riedel@reachmarkets.com.au

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

Targeted Therapy

PTX-100: is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX-100 is believed to be the only GGT-1 inhibitor in the world in clinical development. PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of hematological and solid malignancies. PTX-100 has recently completed a Phase 1b expansion cohort study in T cell lymphomas, where it showed encouraging efficacy and safety. The US FDA has granted PTX-100 Orphan Drug Designation for all T Cell Lymphomas and Fast Track Designation for the treatment of adults with relapsed or refractory (r/r) mycosis fungoides, the most common subtype of CTCL. A Phase 2 study in Cutaneous T cell lymphoma (CTCL) has completed the first dose in a patient and expects to enrol up to 40 patients in the phase 2a part of the trial.

For personal use only

Cell Therapy Platforms

CellPryme-M: Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPryme-M.

CellPryme-A: CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increases tumour penetration of CAR-T cells. CellPryme-A improves tumour killing and host survival of CAR-T cell therapies, and these benefits are even greater when used in conjunction with CellPryme-M pre-treated CAR-T cells.

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post- translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets. OmniCAR is in pre-clinical development.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Find out more at www.ptxtherapeutics.com or connect with us via [LinkedIn](#).

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally,

and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward- looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward- looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any